<DOC>
	<DOCNO>NCT03097211</DOCNO>
	<brief_summary>The purpose study determine whether administration BIA 6-512 ( 25 mg , 50 mg , 75 mg 100 mg ) steady-state affect pharmacokinetics levodopa administer combination single-dose immediate release levodopa/benserazide 200/50 mg single-dose immediate release levodopa/benserazide 200/50 mg plus single-dose nebicapone 150 mg .</brief_summary>
	<brief_title>Effect BIA 6-512 Steady-state Levodopa Pharmacokinetics With Single-dose Levodopa/Benserazide 200/50 mg With Single-dose Levodopa/Benserazide 200/50 mg Plus Single-dose Nebicapone 150 mg</brief_title>
	<detailed_description>Single centre , double-blind , randomise , placebo-controlled , rise multiple dose study four sequential group healthy male female subject . Eligible subject admit Human Pharmacology Unit ( UFH ) day prior receive first study medication . Starting morning Day 1 ( first dose ) , subject receive BIA 6-512/Placebo thrice daily morning Day 5 ( last dose ) . Concomitantly morning dose BIA 6-512/Placebo Day 4 , levodopa/benserazide 200/50 mg ( Madopar® 250 ) single-dose administer . On Day 5 , Madopar® 250 single-dose nebicapone 150 mg single-dose administer concomitantly morning dose BIA 6-512/Placebo . In morning Day 4 Day 5 , product administer fasting condition least 8 hour subject remain fasted 2 h post-dose . Subjects resident UFH admission ( Day 0 ) least 24 h post last dose ( Day 6 ) ; , discharge return follow-up visit .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Benserazide</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<mesh_term>Benserazide , levodopa drug combination</mesh_term>
	<criteria>Male female subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 30 kg/m2 , inclusive . Subjects healthy determine prestudy medical history , physical examination , vital sign , complete neurological examination 12lead ECG . Subjects negative test HBsAg , antiHCVAb HIV1 HIV2 Ab screen Subjects clinical laboratory test result clinically acceptable screen admission . Subjects negative screen alcohol drug abuse screen admission . Subjects nonsmoker smoke ≤ 10 cigarette equivalent per day . Subjects able willing give write informed consent . ( If female ) She childbearing potential reason surgery , childbearing potential , use one follow method contraception : double barrier , intrauterine device abstinence . ( If female ) She negative urine pregnancy test screen admission . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history relevant drug hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 14 unit alcohol week . Subjects significant infection know inflammatory process screen admission . Subjects acute gastrointestinal symptom ( e.g. , nausea , vomit , diarrhoea , heartburn ) time screen admission . Subjects use medicine within 2 week admission may affect safety study assessment , investigator 's opinion . Subjects previously participate clinical trial BIA 6512 . Subjects use investigational drug participate clinical trial within 6 month prior screen . Subjects participate 2 clinical trial within 12 month prior screen . Subjects donate received blood blood product within 3 month prior screen . Subjects vegetarian , vegan medical dietary restriction . Subjects communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent . ( If female ) She pregnant breastfeeding . ( If female ) She childbearing potential use effective contraceptive method ( doublebarrier , intrauterine device abstinence ) use oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>